[发明专利]用奥滨尤妥珠单抗对CD20阳性B细胞淋巴瘤的治疗

说明书

本发明涉及奥滨尤妥珠单抗的施用速度。

发明领域

本发明涉及奥滨尤妥珠单抗的施用速度。

发明背景

奥滨尤妥珠单抗是一种糖工程化改造的,II型抗CD20单克隆抗体,指示用于治疗B细胞恶性肿瘤。它与它的前辈利妥昔单抗的区别在于具有更低的补体依赖性细胞毒性但增强的抗体依赖性细胞毒性和直接B细胞死亡(NPL1-3,图1)。在比较与奥滨尤妥珠单抗或利妥昔单抗任一组合的化疗,继以抗CD20抗体维持疗法的III期GALLIUM试验中,基于奥滨尤妥珠单抗的免疫化疗在具有先前未治疗的滤泡性淋巴瘤(FL)的患者中导致临床上有意义的无进展存活改善(NPL4,5)。在III期GADOLIN研究中在利妥昔单抗不应性的具有无痛性B细胞非霍奇金淋巴瘤(NHL)的患者中奥滨尤妥珠单抗加苯达莫司汀,继以奥滨尤妥珠单抗维持也相对于苯达莫司汀单一疗法改善功效(NPL6)。

引用列表

非专利文献

[NPL1]Mossner E,Brunker P,Moser S,et al.Increasing the efficacy ofCD20 antibody therapy through the engineering of a new type II anti-CD20antibody with enhanced direct and immune effector cell-mediated B-cellcytotoxicity.Blood 2010；115:4393-402.

[NPL2]Herter S,Herting F,Mundigl O,et al.Preclinical activity of thetype II CD20 antibody GA101(obinutuzumab)compared with rituximab andofatumumab in vitro and in xenograft models.Mol Cancer Ther2013；12:2031-42.

[NPL3]Tobinai K,Klein C,Oya N,Fingerle-Rowson G.Areview ofobinutuzumab(GA101),a novel type II anti-CD20 monoclonal antibody,for thetreatment of patients with B-cell malignancies.Adv Ther 2017；34:324-56.

[NPL4]Marcus R,Davies A,Ando K,et al.Obinutuzumab for the first-linetreatment of follicular lymphoma.N Engl J Med 2017；377:1331-44.

[NPL5]Hiddemann W,Barbui AM,Canales Albendea MA,etal.Immunochemotherapy with obinutuzumab or rituximab in previously untreatedfolllicular lymphoma in the randomised phase III GALLIUM study:analysis bychemotherapy regimen.Hematol Oncol 2017；35:117-9.

[NPL6]Sehn LH,Chua N,Mayer J,et al.Obinutuzumab plus bendamustineversus bendamustine monotherapy in patients with rituximab-refractoryindolent non-Hodgkin lymphoma(GADOLIN):a randomised,controlled,open-label,multicentre,phase 3trial.Lancet Oncol 2016；17:1081-93.